Discover Camcevi.
  • ALREADY
    Set. Go!
DOSING

When you order through AccordConnects*, your practice can enjoy benefits including replenishing inventory with just one click.

Find out more

*Electronic ordering available only through Besse or McKesson

We are constantly working to expand our network of distribution partners and GPOs to make your job easier.

Distribution Partners

Name
Amerisource SD
Telephone
800.543.2111
Order Link
Besse Online
Name
Besse Medical
Telephone
800.543.2111
Order Link
Besse Online
Name
Cardinal SD
Telephone
855.855.0708
Order Link
Specialty Online
Name
CuraScript
Telephone
877.599.7748
Order Link
Order Online
Name
McKesson MPB
Telephone
877.625.2566
Order Link
McKesson Connect
Name
McKesson MSCD Oncology Multispecialty
Telephone
800.482.6700
855.477.9800
Order Link
MSCD Online

GPO Partners

Name
International Urology Network (IUN)
Telephone
800.543.2111
Name
UROGPO
Telephone
404.250.3568
Order Link
Order Online
Name
VitalSource™ GPO
Telephone
877.453.3972
Order Link
Specialty Online
Unity and OnMark GPOs: Information for Oncology Network and specialty practice groups can be found on McKesson’s Customer Portal.

Specialty Pharmacy

Name
Biologics (by McKesson)
Telephone
800-850-4306
Order Link
Biologics by McKesson

Get the original no-mix, convenient, prefilled syringe now with enhanced safety guard1

Use National Drug Code 69448-023-63 to get CAMCEVI with the SurGuard®3 Safety Needle, featuring an integrated arm and sheath needle cover.

NEW NATIONAL DRUG CODE (NDC)

69448-023-63

Look for the new code in your EHR and EMR systems

Contents include:

1 sterile CAMCEVI 42 mg prefilled syringe

1 sterile 18-gauge SurGuard3 Safety Needle

Instructions for Use and Prescribing Information

NOTE: As of April 1, 2025, Accord BioPharma is replacing its current needle with the SurGuard3 Safety Needle. We expect there to be an overlap in inventory for a short period of time during this transition.

Due to changes to coding requirements, you may be required to add new modifiers to Medicare claim forms.

Download coding tip sheetDownload tip sheet

CAMCEVI received pass-through status effective October 1, 2022.*
Payment instructions now available in Oct. 2022 OPPS update.

Download BillingDownload billing &
reimbursement guide

*CMS Status Indicator = G (Pass-through Drugs and Biologicals).

    ×

    *CMS Status Indicator = G (Pass-through Drugs and Biologicals).

    DON’T SWEAT INVENTORY MANAGEMENT

    Stay steps ahead of your inventory with AccordConnects®

    Visit accordconnects.com or

    Download the app
    Accord-Connects-iphone

      connect with a CAMCEVI® representative

      Complete the forms with your information to reach a CAMCEVI representative near you.

      *Required fields

      IMPORTANT SAFETY INFORMATION

      Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

      CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications.

      Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

      Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

      Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.

      Androgen deprivation therapy may prolong the QT/QTc interval. Consider periodic monitoring of electrocardiograms and electrolytes.

      Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

      CAMCEVI can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Interrupt CAMCEVI if signs or symptoms of SCARs develop. Permanently discontinue if SCARs are confirmed.

      Monitor serum levels of testosterone following injection of CAMCEVI.

      Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

      The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

      INDICATION

      CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

      Click here for full Prescribing Information.

      Back to TopBack to Top button

      Reference:

      1. CAMCEVI. Prescribing information. Accord BioPharma.

      Back to TopBack to Top button